Investing in Fast growing Companies
We call ourselves Growth Buyout investors, which summarizes the strategy of SHS to invest in both – buyout transactions in established companies as well as growth investments in scale-up companies in the healthcare field.
Private
Equity
Our investment focus is on established, growing companies positioned within fast-developing verticals in the healthcare industry.
As Germany’s leading investor for healthcare companies, we bring not only capital, but also strategic expertise as well as synergy effects from our portfolio into a partnership.
SHS Capital’s value proposition is further amplified by its extensive network within the healthcare realm which has grown for more than past 30 years by fostering relationships with a diverse array of professionals, from leading KOLs to seasoned industry leaders.
Opportunities for Private Equity
Succession
As an investor with experience in the sector, SHS has already successfully implemented a large number of company successions for healthcare companies.
International expansion
SHS has already supported many medium-sized companies with capital and expertise in order to implement their plans to expand into the USA or Asia.
Minority shareholdings
We help owners in getting their company to the next level by adding complementary teams from our network or helping to improve internal processes, setting up direct sales teams or scaling up manufacturing.
We bring into a partnership
Growth
Financing
Our growth investments focus is on companies having started the commercialization of their cutting-edge technologies.
With our investments, we help shape European champions in their respective healthcare segments or support them in their further expansion.
In addition to capital, we essentially provide our networks and expertise in the areas of approval and reimbursement (USA/China), development of stable organizational structures, marketing/sales, M&A and exit.
Growth capital
possibilities
Financing rollout
Our portfolio companies benefit from our long-standing relationships with the leading players in the healthcare sector in Europe, such as corporates, hospitals and insurance companies.
Financing FDA approval
Thanks to our many years of experience, working together can prevent time-consuming loops in the approval process.
Financing clinical studies
In addition to capital, our portfolio companies benefit from our contacts to the leading study centers and consultants in Europe.
